Q2-osavuosiraportti
71 päivää sitten‧45 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
10 576
Myynti
Määrä
58 895
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 76 | - | - | ||
| 500 | - | - | ||
| 9 789 | - | - | ||
| 211 | - | - | ||
| 2 143 | - | - |
Ylin
0,333VWAP
Alin
0,313VaihtoMäärä
1 3 171 805
VWAP
Ylin
0,333Alin
0,313VaihtoMäärä
1 3 171 805
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 171 805 | 3 171 805 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 171 805 | 3 171 805 | 0 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 26.11. |
| Menneet tapahtumat | ||
|---|---|---|
| Merkintäoikeusanti | 2.10. | |
| 2025 Ylimääräinen yhtiökokous | 29.9. | |
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2025 Q1-osavuosiraportti | 14.5. | |
| 2024 Yhtiökokous | 14.5. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·8 t sitten · Muokattu10 minutes old message: https://www.linkedin.com/posts/immunovia-ab_pancreasure-clariti-verifi-activity-7392561623246336002-sWGh?utm_source=li_share&utm_content=feedcontent&utm_medium=g_mb_web&utm_campaign=copy and https://www.linkedin.com/posts/patricio-polanco-b4bbabb5_pancreaticcancer-activity-7389524211565965312-7pE8 High quality data is the foundation of the #PancreaSure test. Dr. PATRICIO POLANCO presented the pooled analysis of our two validation studies, #CLARITI and #VERIFI, as a plenary talk at the 2025 American College of Gastroenterology conference in Phoenix last week. #PancreaticCancerAwareness8 t sitten8 t sittenAI analyse Key Takeaways from the Post: Validation by Key Opinion Leader (KOL): The post is authored by a leading surgical oncologist who is presenting the data. This endorsement from a Key Opinion Leader (KOL) in the surgical community is crucial for building trust and accelerating adoption among referring physicians and high-risk surveillance centers. Multi-Center Collaboration: Polanco mentions his "multicenter study on a novel serum biomarker." This refers to the collaboration involving major institutions, including the MD Anderson Cancer Center (as shown in the image with the names of the co-authors and centers). Core Message: The post praises the development of a "great privilege to present our multicenter study on a novel serum biomarker for early detection of #PancreaticCancer." He calls it "Exciting data and promising tool for high-risk population!" Why This is the "Fuel" for Acceleration This type of advocacy is essential for Immunovia's immediate goals and helps the CEO, Jeff Borcherding, with the following: Clinical Utility Proof: Seeing a senior surgeon validate the tool indicates that the test is being integrated into, and is useful for, clinical decision-making (clinical utility). This is the key element payors (insurance) are waiting for. De-risking the Partnership: When a major partner reviews Immunovia, they look for proof that their large, expensive sales force won't face resistance from the medical community. Posts like this, coupled with rising adoption rates, significantly de-risk the commercial launch because the KOLs are already advocating for the product. Building Momentum: This advocacy fuels the "targeted advocacy" stage, driving word-of-mouth and initial volume among the most critical early adopters—exactly what is needed to generate the sales figures that accelerate a partnership deal. In short, while the financial accelerator is the partnership deal itself, the clinical and marketing fuel that makes that deal happen comes from successful execution and validation demonstrated in posts like this.- ·8 t sitten · MuokattuQuite heavily short traded. Hoping for a short squeeze one of these days :D 14. Immunovia 6,1% (5,6) https://www.nordnet.no/market/news/5193a091-306d-4468-b7e0-1e51073498e3
- ·9 t sitten · MuokattuI feel like I'm already seeing a convergence between the share and the BTA-part of the limited company. The period with BTA is surely over by Monday, isn't it? Asked AI, it says that 2 kroner old price should be worth kr 1,86. Value loss per share of 14 öre. Can that be right? Old text: Also, I'm wondering a bit about beyond 2025. Since the share is actually worth close to 50 öre if one uses the dilution factor based on the approx. 1. September stock market price. Will then 1 krone be the new 2 kroner level? Dilution-wise.·9 t sitten · MuokattuAsked it to calculate TERP for me: Old price <--> TERP price <-> % dilution <-> % final gain from old price SEK 0,32 -- 0,317 - 0,52% - 24,35% SEK 0,9 -- 0,85 - 5,56% - 18,06% SEK 1,00 -- 0,942 - 5,83% - 17,71% SEK 1,2 -- 1,125 - 6,25% - 17,19% SEK 1,4 -- 1,308 - 6,55% - 16,82% SEK 1,6 -- 1,492 - 6,77% - 16,54% SEK 1,8 -- 1,675 - 6,94% - 16,32% SEK 2,00 -- 1,858 - 7,08% - 16,15% SEK 3,00 -- 2,775 - 7,5% - 15,62% SEK 4,00 -- 3,692 - 7,71% - 15,36% Do I understand this completely myself yet, No :D
- ·2 päivää sitten · MuokattuWe need a little positive reminder. Note, 2 weeks old. Best part of it: ".. enables us to pursue licensure in the states of California and New York, both large and attractive markets." https://www.linkedin.com/posts/jeff-borcherding_earlier-this-week-we-announced-that-the-immunovia-activity-7384913590392324096-mtvs Jeff Borcherding Chief Executive Officer at Immunovia 2w Earlier this week we announced that the Immunovia AB lab in North Carolina was awarded accreditation by the College of American Pathologists (CAP). Why does this matter? At least three reasons: 1. It confirms our commitment to meeting the highest standards for lab quality, accuracy and patient safety. 2. It provides reassurance to clinicians and patients that they can rely on the quality of PancreaSure test results. 3. CAP accreditation enables us to pursue licensure in the states of California and New York, both large and attractive markets. Onward
- ·2 päivää sitten · MuokattuRemember that short interest is over 6 %, that is high and exposes them to high risk and expensive loans. This is no longer correct! From us who are "long" investors. This thing with short traders being allowed to run rampant. The share price is below the subscription price. This does not align with the company's close to 50 öre real value. It is possibly temporary. Is the stock on a bargain sale now?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
71 päivää sitten‧45 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·8 t sitten · Muokattu10 minutes old message: https://www.linkedin.com/posts/immunovia-ab_pancreasure-clariti-verifi-activity-7392561623246336002-sWGh?utm_source=li_share&utm_content=feedcontent&utm_medium=g_mb_web&utm_campaign=copy and https://www.linkedin.com/posts/patricio-polanco-b4bbabb5_pancreaticcancer-activity-7389524211565965312-7pE8 High quality data is the foundation of the #PancreaSure test. Dr. PATRICIO POLANCO presented the pooled analysis of our two validation studies, #CLARITI and #VERIFI, as a plenary talk at the 2025 American College of Gastroenterology conference in Phoenix last week. #PancreaticCancerAwareness8 t sitten8 t sittenAI analyse Key Takeaways from the Post: Validation by Key Opinion Leader (KOL): The post is authored by a leading surgical oncologist who is presenting the data. This endorsement from a Key Opinion Leader (KOL) in the surgical community is crucial for building trust and accelerating adoption among referring physicians and high-risk surveillance centers. Multi-Center Collaboration: Polanco mentions his "multicenter study on a novel serum biomarker." This refers to the collaboration involving major institutions, including the MD Anderson Cancer Center (as shown in the image with the names of the co-authors and centers). Core Message: The post praises the development of a "great privilege to present our multicenter study on a novel serum biomarker for early detection of #PancreaticCancer." He calls it "Exciting data and promising tool for high-risk population!" Why This is the "Fuel" for Acceleration This type of advocacy is essential for Immunovia's immediate goals and helps the CEO, Jeff Borcherding, with the following: Clinical Utility Proof: Seeing a senior surgeon validate the tool indicates that the test is being integrated into, and is useful for, clinical decision-making (clinical utility). This is the key element payors (insurance) are waiting for. De-risking the Partnership: When a major partner reviews Immunovia, they look for proof that their large, expensive sales force won't face resistance from the medical community. Posts like this, coupled with rising adoption rates, significantly de-risk the commercial launch because the KOLs are already advocating for the product. Building Momentum: This advocacy fuels the "targeted advocacy" stage, driving word-of-mouth and initial volume among the most critical early adopters—exactly what is needed to generate the sales figures that accelerate a partnership deal. In short, while the financial accelerator is the partnership deal itself, the clinical and marketing fuel that makes that deal happen comes from successful execution and validation demonstrated in posts like this.
- ·8 t sitten · MuokattuQuite heavily short traded. Hoping for a short squeeze one of these days :D 14. Immunovia 6,1% (5,6) https://www.nordnet.no/market/news/5193a091-306d-4468-b7e0-1e51073498e3
- ·9 t sitten · MuokattuI feel like I'm already seeing a convergence between the share and the BTA-part of the limited company. The period with BTA is surely over by Monday, isn't it? Asked AI, it says that 2 kroner old price should be worth kr 1,86. Value loss per share of 14 öre. Can that be right? Old text: Also, I'm wondering a bit about beyond 2025. Since the share is actually worth close to 50 öre if one uses the dilution factor based on the approx. 1. September stock market price. Will then 1 krone be the new 2 kroner level? Dilution-wise.·9 t sitten · MuokattuAsked it to calculate TERP for me: Old price <--> TERP price <-> % dilution <-> % final gain from old price SEK 0,32 -- 0,317 - 0,52% - 24,35% SEK 0,9 -- 0,85 - 5,56% - 18,06% SEK 1,00 -- 0,942 - 5,83% - 17,71% SEK 1,2 -- 1,125 - 6,25% - 17,19% SEK 1,4 -- 1,308 - 6,55% - 16,82% SEK 1,6 -- 1,492 - 6,77% - 16,54% SEK 1,8 -- 1,675 - 6,94% - 16,32% SEK 2,00 -- 1,858 - 7,08% - 16,15% SEK 3,00 -- 2,775 - 7,5% - 15,62% SEK 4,00 -- 3,692 - 7,71% - 15,36% Do I understand this completely myself yet, No :D
- ·2 päivää sitten · MuokattuWe need a little positive reminder. Note, 2 weeks old. Best part of it: ".. enables us to pursue licensure in the states of California and New York, both large and attractive markets." https://www.linkedin.com/posts/jeff-borcherding_earlier-this-week-we-announced-that-the-immunovia-activity-7384913590392324096-mtvs Jeff Borcherding Chief Executive Officer at Immunovia 2w Earlier this week we announced that the Immunovia AB lab in North Carolina was awarded accreditation by the College of American Pathologists (CAP). Why does this matter? At least three reasons: 1. It confirms our commitment to meeting the highest standards for lab quality, accuracy and patient safety. 2. It provides reassurance to clinicians and patients that they can rely on the quality of PancreaSure test results. 3. CAP accreditation enables us to pursue licensure in the states of California and New York, both large and attractive markets. Onward
- ·2 päivää sitten · MuokattuRemember that short interest is over 6 %, that is high and exposes them to high risk and expensive loans. This is no longer correct! From us who are "long" investors. This thing with short traders being allowed to run rampant. The share price is below the subscription price. This does not align with the company's close to 50 öre real value. It is possibly temporary. Is the stock on a bargain sale now?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
10 576
Myynti
Määrä
58 895
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 76 | - | - | ||
| 500 | - | - | ||
| 9 789 | - | - | ||
| 211 | - | - | ||
| 2 143 | - | - |
Ylin
0,333VWAP
Alin
0,313VaihtoMäärä
1 3 171 805
VWAP
Ylin
0,333Alin
0,313VaihtoMäärä
1 3 171 805
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 171 805 | 3 171 805 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 171 805 | 3 171 805 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 26.11. |
| Menneet tapahtumat | ||
|---|---|---|
| Merkintäoikeusanti | 2.10. | |
| 2025 Ylimääräinen yhtiökokous | 29.9. | |
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2025 Q1-osavuosiraportti | 14.5. | |
| 2024 Yhtiökokous | 14.5. |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
71 päivää sitten‧45 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 26.11. |
| Menneet tapahtumat | ||
|---|---|---|
| Merkintäoikeusanti | 2.10. | |
| 2025 Ylimääräinen yhtiökokous | 29.9. | |
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2025 Q1-osavuosiraportti | 14.5. | |
| 2024 Yhtiökokous | 14.5. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·8 t sitten · Muokattu10 minutes old message: https://www.linkedin.com/posts/immunovia-ab_pancreasure-clariti-verifi-activity-7392561623246336002-sWGh?utm_source=li_share&utm_content=feedcontent&utm_medium=g_mb_web&utm_campaign=copy and https://www.linkedin.com/posts/patricio-polanco-b4bbabb5_pancreaticcancer-activity-7389524211565965312-7pE8 High quality data is the foundation of the #PancreaSure test. Dr. PATRICIO POLANCO presented the pooled analysis of our two validation studies, #CLARITI and #VERIFI, as a plenary talk at the 2025 American College of Gastroenterology conference in Phoenix last week. #PancreaticCancerAwareness8 t sitten8 t sittenAI analyse Key Takeaways from the Post: Validation by Key Opinion Leader (KOL): The post is authored by a leading surgical oncologist who is presenting the data. This endorsement from a Key Opinion Leader (KOL) in the surgical community is crucial for building trust and accelerating adoption among referring physicians and high-risk surveillance centers. Multi-Center Collaboration: Polanco mentions his "multicenter study on a novel serum biomarker." This refers to the collaboration involving major institutions, including the MD Anderson Cancer Center (as shown in the image with the names of the co-authors and centers). Core Message: The post praises the development of a "great privilege to present our multicenter study on a novel serum biomarker for early detection of #PancreaticCancer." He calls it "Exciting data and promising tool for high-risk population!" Why This is the "Fuel" for Acceleration This type of advocacy is essential for Immunovia's immediate goals and helps the CEO, Jeff Borcherding, with the following: Clinical Utility Proof: Seeing a senior surgeon validate the tool indicates that the test is being integrated into, and is useful for, clinical decision-making (clinical utility). This is the key element payors (insurance) are waiting for. De-risking the Partnership: When a major partner reviews Immunovia, they look for proof that their large, expensive sales force won't face resistance from the medical community. Posts like this, coupled with rising adoption rates, significantly de-risk the commercial launch because the KOLs are already advocating for the product. Building Momentum: This advocacy fuels the "targeted advocacy" stage, driving word-of-mouth and initial volume among the most critical early adopters—exactly what is needed to generate the sales figures that accelerate a partnership deal. In short, while the financial accelerator is the partnership deal itself, the clinical and marketing fuel that makes that deal happen comes from successful execution and validation demonstrated in posts like this.
- ·8 t sitten · MuokattuQuite heavily short traded. Hoping for a short squeeze one of these days :D 14. Immunovia 6,1% (5,6) https://www.nordnet.no/market/news/5193a091-306d-4468-b7e0-1e51073498e3
- ·9 t sitten · MuokattuI feel like I'm already seeing a convergence between the share and the BTA-part of the limited company. The period with BTA is surely over by Monday, isn't it? Asked AI, it says that 2 kroner old price should be worth kr 1,86. Value loss per share of 14 öre. Can that be right? Old text: Also, I'm wondering a bit about beyond 2025. Since the share is actually worth close to 50 öre if one uses the dilution factor based on the approx. 1. September stock market price. Will then 1 krone be the new 2 kroner level? Dilution-wise.·9 t sitten · MuokattuAsked it to calculate TERP for me: Old price <--> TERP price <-> % dilution <-> % final gain from old price SEK 0,32 -- 0,317 - 0,52% - 24,35% SEK 0,9 -- 0,85 - 5,56% - 18,06% SEK 1,00 -- 0,942 - 5,83% - 17,71% SEK 1,2 -- 1,125 - 6,25% - 17,19% SEK 1,4 -- 1,308 - 6,55% - 16,82% SEK 1,6 -- 1,492 - 6,77% - 16,54% SEK 1,8 -- 1,675 - 6,94% - 16,32% SEK 2,00 -- 1,858 - 7,08% - 16,15% SEK 3,00 -- 2,775 - 7,5% - 15,62% SEK 4,00 -- 3,692 - 7,71% - 15,36% Do I understand this completely myself yet, No :D
- ·2 päivää sitten · MuokattuWe need a little positive reminder. Note, 2 weeks old. Best part of it: ".. enables us to pursue licensure in the states of California and New York, both large and attractive markets." https://www.linkedin.com/posts/jeff-borcherding_earlier-this-week-we-announced-that-the-immunovia-activity-7384913590392324096-mtvs Jeff Borcherding Chief Executive Officer at Immunovia 2w Earlier this week we announced that the Immunovia AB lab in North Carolina was awarded accreditation by the College of American Pathologists (CAP). Why does this matter? At least three reasons: 1. It confirms our commitment to meeting the highest standards for lab quality, accuracy and patient safety. 2. It provides reassurance to clinicians and patients that they can rely on the quality of PancreaSure test results. 3. CAP accreditation enables us to pursue licensure in the states of California and New York, both large and attractive markets. Onward
- ·2 päivää sitten · MuokattuRemember that short interest is over 6 %, that is high and exposes them to high risk and expensive loans. This is no longer correct! From us who are "long" investors. This thing with short traders being allowed to run rampant. The share price is below the subscription price. This does not align with the company's close to 50 öre real value. It is possibly temporary. Is the stock on a bargain sale now?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
10 576
Myynti
Määrä
58 895
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 76 | - | - | ||
| 500 | - | - | ||
| 9 789 | - | - | ||
| 211 | - | - | ||
| 2 143 | - | - |
Ylin
0,333VWAP
Alin
0,313VaihtoMäärä
1 3 171 805
VWAP
Ylin
0,333Alin
0,313VaihtoMäärä
1 3 171 805
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 171 805 | 3 171 805 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 171 805 | 3 171 805 | 0 | 0 |